Korro Bio DEF 14A: Executive Compensation Details
Ticker: KRRO · Form: DEF 14A · Filed: Apr 29, 2025 · CIK: 1703647
| Field | Detail |
|---|---|
| Company | Korro Bio, Inc. (KRRO) |
| Form Type | DEF 14A |
| Filed Date | Apr 29, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, def-14a, equity-awards
TL;DR
Korro Bio dropped its DEF 14A showing exec comp for 2024 - check out equity awards for LLucchino & Aiyar.
AI Summary
Korro Bio, Inc. filed a DEF 14A on April 29, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on equity awards granted to key personnel such as David LLucchino and Dr. Aiyar, with details on their fair value and vesting conditions. The company, formerly Frequency Therapeutics, Inc., is in the pharmaceutical preparations industry.
Why It Matters
This filing provides transparency into how Korro Bio compensates its top executives, which can influence investor perception and employee morale.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of executive compensation and does not inherently present new financial risks.
Key Numbers
- 2024 — Fiscal Year End (Compensation data pertains to this year.)
- 2023 — Prior Fiscal Year (Comparative compensation data is included.)
Key Players & Entities
- Korro Bio, Inc. (company) — Filer of the DEF 14A
- Frequency Therapeutics, Inc. (company) — Former name of Korro Bio, Inc.
- David LLucchino (person) — Executive mentioned in compensation details
- Dr. Aiyar (person) — Executive mentioned in compensation details
- 2024-12-31 (date) — Fiscal year end for compensation reporting
- 20250429 (date) — Filing date of the DEF 14A
FAQ
What was the fair value of equity awards granted to David LLucchino in the covered year?
The filing indicates details for 'YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember' for David LLucchino, with data for 2024-01-01 to 2024-12-31, but specific dollar amounts are not provided in this excerpt.
What is the change in fair value of outstanding equity awards granted in prior years for non-personnel?
The filing references 'ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember' for non-personnel, with data points for both 2024 and 2023 fiscal years, but specific values are not in this excerpt.
When did Korro Bio change its name from Frequency Therapeutics, Inc.?
The date of the name change from Frequency Therapeutics, Inc. to Korro Bio, Inc. was April 12, 2017.
What is Korro Bio's Standard Industrial Classification (SIC) code?
Korro Bio, Inc.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
What is the business address of Korro Bio, Inc.?
The business address for Korro Bio, Inc. is 60 First Street, 2nd Floor, Suite 250, Cambridge, MA 02141.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 29, 2025 by David LLucchino regarding Korro Bio, Inc. (KRRO).